Role of VISTA in AML immune evasion
Official title: Investigating the Role of VISTA in Driving Immune Evasion in Acute Myeloid Leukemia
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11418478 · Data updated 2026-11-12
A companying therapy goal is to block a specific immune brake (VISTA) to help the immune system fight acute myeloid leukemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 22, 2025 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $654,837 |
| NIH project number | 5R01CA302819-02 |
| Project ID | NIH-11418478 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with acute myeloid leukemia who could benefit from novel immunotherapies (e.g., those who relapse or do not respond to standard therapy).
✕Less likely to help
Patients whose AML does not respond to VISTA-targeted strategies or who cannot tolerate experimental therapies may not benefit.
What this research studies
This project studies how the immune checkpoint VISTA affects immune cells in AML and whether blocking VISTA can make leukemia cells more visible to the immune system. It will explore the signaling pathways in myeloid cells and test VISTA inhibitors in preclinical AML models. If successful, the work could lead to new immune-based treatments for AML patients. The research is conducted at the Cleveland Clinic Lerner and Case Western Reserve University, led by Dr. Lily Wang.
Why it matters
Potential benefit: If successful, this work could pave the way for new immunotherapies that boost anti-leukemia immune responses in patients with AML.
How similar studies have gone: Preclinical studies in immune checkpoint research have shown potential in modulating anti-tumor immunity, though translation to AML is still under investigation.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Wang, Li Lily — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Wang, Li Lily
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.